<DOC>
	<DOCNO>NCT00416208</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety consolidation therapy bortezomib patient multiple myeloma age 61 75 .</brief_summary>
	<brief_title>Consolidation Therapy With Bortezomib Elderly Patients With Multiple Myeloma</brief_title>
	<detailed_description>No data support use bortezomib consolidation therapy multiple myeloma patient available . √çnterferon test consolidation / maintenance therapy uniformly proven prolong survival . In study hypothesis test bortezomib able increase duration response thus improve survival . This hypothesis base result approval study bortezomib test improve endpoints.This multicenter , open-label , randomize ( patient assign different treatment group chance ) phase III study evaluate efficacy safety consolidation therapy bortezomib patient multiple myeloma age 61 75 . Three month receive high dose melphalan autologous stem cell transplantation patient randomize receive either consolidation therapy bortezomib monitor without consolidation therapy . Subjects consolidation group treat 4 cycle ( 6 week ) . The main study phase duration 24 week . The trial end last enrolled patient complete follow-up period 30 month . The primary objective determine event free survival treatment observation group . The secondary objective assess response rate , overall survival , duration response , time progression , short- long-term toxicity , quality life cytogenetic analysis regard treatment response , event free survival overall survival . Primary efficacy analysis : Event free survival define time first disease-related therapeutic procedure death , progress relapse . Secondary efficacy analysis : response rate treatment group ( measure relative change M-protein level serum urine ) ; overall survival define time first therapeutic procedure death ; time progression define duration date enrolment date first document evidence progressive disease relapse ; duration response define duration month date first evidence confirm response date first document evidence progressive disease relapse ; quality life assess questionnaire EORTC QLQ-C30 ( Quality life questionnaire ) EORTC EQ-5D ( Euro Quality life ) . Consolidation therapy last 4 cycle . Subjects treat bortezomib 1.6 mg/m2 body surface intravenously weekly 4 week ( Days 1 , 8 , 15 , 22 ) follow 13-day rest period ( day 23 35 ) . At least 72 hour relapse consecutive dos bortezomib . Therapy withhold onset Grade 3 nonhematological Grade 4 hematological toxicity exclude neuropathy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients pretreatment single tandem high dose melphalan therapy autologous stem cell transplantation first line therapy least stable disease stem cell transplantation adequate hematological , hepatic renal lab parameter karnofsky status 70 nonsecretory multiple myeloma previous treatment bortezomib allogenic stem cell transplantation coexist malignancy beside basaliome peripheral neuropathy epilepsia severe comorbidities ( renal , hepatic , cardiovascular , metabolic , infectious etc . ) history allergic reaction bortezomib mannitol expect life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>PS341</keyword>
	<keyword>Proteasome inhibitor</keyword>
	<keyword>Consolidation therapy</keyword>
</DOC>